Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pim-3 shRNA
- Development stage
- Preclinical
- Lead developer
- North Carolina Central University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Pim-3 shRNA is a short hairpin RNA designed to silence the expression of the Pim-3 kinase, a member of the proviral integration site for Moloney murine leukemia virus (Pim) family of serine/threonine kinases. Pim-3 is often aberrantly expressed in solid tumors, including pancreatic ductal adenocarcinoma (PDAC), where it contributes to cell survival and chemoresistance. By targeting Pim-3 mRNA for degradation via the RNA interference (RNAi) pathway, this shRNA inhibits cell growth, induces cell cycle arrest in the G1 or S phase, and promotes apoptosis. Furthermore, downregulation of Pim-3 has been shown to sensitize pancreatic cancer cells to gemcitabine treatment, potentially by reducing the activity of multidrug resistance protein 1 (MDR1).
- Other names
- Pim-3 short hairpin RNAPim3 short hairpin RNAPim 3 short hairpin RNA
02
Targets
PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)
Beyond the preview
Go deeper on Pim-3 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pim-3 shRNA.